Xenical ships in 6 generic brands through our lane. The drug works. The side effects are why most people quit by month 3.

Orlistat is the only FDA-approved weight-loss drug that works in your gut instead of your brain.

That's the marketing story. The real story is that it works exactly as advertised — blocking ~30% of dietary fat from being absorbed — and that's why people quit it.

$15-50/month for 90 caps through our lane vs $200-300 brand. Six generic brands, two doses (60mg Alli-equivalent + 120mg Xenical-equivalent). The drug works. The side effects are why most people quit by month 3.

If 30% of dinner's fat doesn't get digested, it has to leave somewhere. It leaves the way 30% of any unprocessed fat leaves a body: oily, urgent, and on whatever schedule your colon picks, not yours.

This is not a side effect. This is the mechanism.

The number that decides whether you'll last on this drug: 26.6%.

That's the FDA Xenical label rate of "oily spotting" in the 4-year XENDOS trial cohort (Torgerson 2004, Diabetes Care 27(1):155-161). Plus 22.1% "fecal urgency." Plus 20.0% "fatty/oily stool." Plus 7.7% "fecal incontinence" — actual involuntary leakage of stool, which the label calls out by name.

These aren't rare events. The FDA Xenical label lists them as the expected profile of treatment. The trial wasn't measuring a malfunction; it was measuring how the drug works.

Orlistat is a pancreatic lipase inhibitor. It binds the enzyme that splits dietary triglyceride into absorbable free fatty acids. With the enzyme blocked, ~30% of the fat in any meal stays as triglyceride. Triglyceride doesn't absorb across intestinal mucosa. So it transits the bowel and exits.

If you eat 70g of fat at dinner, ~21g of triglyceride passes through and out. That's roughly an espresso shot of liquid fat looking for an exit.

Your gut is now an oil-water separator with a deadline.

What the trial data actually shows

Drop the side-effect data and the efficacy data is honest. Orlistat works. Just modestly.

XENDOS (Torgerson 2004) — 3,304 obese adults, orlistat 120mg three times daily plus lifestyle counseling vs placebo plus lifestyle counseling, 4 years.

• Year 1: -10.6 kg orlistat vs -6.2 kg placebo (~6.9% body weight vs ~4.1%).
• Year 4: -5.8 kg orlistat vs -3.0 kg placebo. Most of the weight crept back on both arms.
• Type 2 diabetes incidence: 6.2% orlistat vs 9.0% placebo. 37.3% relative risk reduction in new diabetes diagnoses.

That last number is the only orlistat statistic that consistently impresses anyone. The drug doesn't make people skinny. It does, in the prediabetic-and-overweight cohort, meaningfully delay or prevent the metabolic transition into type 2 diabetes.

For comparison: STEP-1 semaglutide 2.4mg injection at 68 weeks delivered -14.9% body weight. Tirzepatide at 72 weeks delivered ~-20.9%. Orlistat at one year delivers ~7%, the same range as a serious lifestyle intervention.

Plus: 30% fat blockade = 30% fat-soluble vitamin (A/D/E/K) blockade. Multivit at bedtime, 2hr from orlistat. Non-negotiable. Protocol below.

This is why orlistat looked like a serious obesity drug in 1999 and looks like a niche option in 2026. The bar moved.

The two doses, two regulatory routes

Orlistat 120mg ships under FDA Rx (Xenical, approved 1999). Orlistat 60mg ships OTC in the US (Alli, approved 2007). The 60mg formulation gets ~85% of the 120mg's effect because lipase inhibition is non-linear — once you saturate the enzyme in the gut lumen, more drug doesn't capture proportionally more fat.

Alli is the over-the-counter compromise. Lower side effects, ~25% fat blockade instead of ~30%, fewer bathroom emergencies per week, slightly less weight loss. The trade is real and rational for someone who'd rather lose 4-5% over a year than 7% with full Xenical-grade GI consequences.

Brand prices in the US:

• Xenical 120mg, 90 caps: $200-300/month at retail cash.
• Alli 60mg, 120 caps OTC: $40-80/month depending on pack size and retailer.

Behind both labels is the same molecule. Same Cheplapharm-licensed (Roche divested Xenical to Cheplapharm in 2018) supply chain into the US, same GSK-distributed Alli OTC line.

The 6-brand generic teardown

LiberaCure routes six orlistat brands. Slimtop and Reeshape ship in BOTH 60mg (Alli-equivalent) and 120mg (Xenical-equivalent) doses; Obelit, Orlica, Orliford, Orligal ship 120mg only.

60mg vs 120mg picking guide. Pick 60mg if never tried orlistat (lower GI risk, ~85% effect). Pick 120mg if you've tolerated 60mg for 2-4 weeks and want full Xenical-grade fat blockade.

All six are bioequivalent generic orlistat per Indian CDSCO standards. The molecule is identical. What differs is which manufacturer's facility ships the capsule and which packaging arrives at your door.

Among the manufacturers, Torrent Pharmaceuticals (behind Orlica) is the same company that ships our oral semaglutide tablet (Sembolic) — a top-10 Indian pharma group with USFDA-inspected facilities and EU export approvals. Intas Pharmaceuticals (Obelit) is similarly large and runs USFDA-inspected facilities. The remaining four — Healing Pharma, Meyer Organics, Banford, Signature — are niche specialty manufacturers focused on the export men's-health and weight-management lanes. All run WHO-GMP facilities. None of them are doing anything exotic with the orlistat molecule itself.

LiberaCure-routed pricing on all six sits in the same range: $0.20-0.50 per capsule, $15-50/month for a 90-pack (Slimtop 60mg, Orlica, and Obelit at the higher end; Orligal at the lowest). The brand variation isn't a price ladder — it's a SKU availability question. If we have stock of Obelit this week, you'll get Obelit. Next month it might be Orligal. The molecule is the same.

That delivers the 30-60x cost compression vs Xenical at retail, which is roughly the same compression we see on tadalafil, finasteride, and most other off-patent molecules where the brand price never came down because nobody renegotiated.

The cost stack, monthly

The compounded-pharmacy lane that's still big for semaglutide is mostly absent for orlistat. Orlistat was never on FDA shortage lists, so the compounding-loophole flow that powered cheap GLP-1 in 2022-2024 doesn't extend to lipase inhibitors. The cost choice is brand vs personal-import generic, no clever middle.

The metaphor: orlistat is the airport security frisker.

GLP-1s work centrally. They turn the appetite signal down. You eat less. The drug isn't asking your body to do anything socially awkward.

Orlistat works peripherally. It sits in your gut and frisks every fatty meal, and 30% of the fat doesn't get on the plane. The frisked fat has to go somewhere. It goes through you, on its own timeline.

Most people, given the choice, would rather take a different flight.

That's the orlistat-vs-GLP-1 trade-off in one paragraph. The drug is operationally clean (oral, no needle, no fridge, no titration ladder). The downstream operational reality is what most people don't survive.

The vitamin protocol nobody tells you about

If you're going to be on orlistat for more than a few weeks, this matters more than the bathroom logistics.

Orlistat blocks fat absorption. Fat-soluble vitamins (A, D, E, K) ride in dietary fat. So orlistat blocks ~30% of fat-soluble vitamin absorption too.

The label fix:

• Take a fat-soluble multivitamin (A, D, E, K) at least 2 hours apart from each orlistat dose.
• Most people take orlistat with meals (3 doses/day) and the multivitamin at bedtime, when no food is being processed.
• Vitamin K matters specifically if you're on warfarin — the interaction can shift INR. Tell your prescriber if you're on anticoagulants.

Unlike GLP-1 monitoring (where the labs to track are A1c, lipids, kidney function), orlistat's labs are vitamin D 25(OH) at baseline and at 6 months, plus prothrombin time / INR if anticoagulated. Both are routine and order-it-yourself in the US through Quest or LabCorp ($30-80 each, no prescription).

When orlistat is actually the right pick

Orlistat is the answer in maybe four specific situations. Outside those, GLP-1 is the better drug.

1. GLP-1 is medically contraindicated, or not accessible. Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Pancreatitis history. Severe gastroparesis. These are real GLP-1 stop-signs, and orlistat doesn't share them. Plus the access angle: Australia's TGA tightened the personal-import GLP-1 lane in 2024-2025, parts of EU restricted off-label semaglutide supply, and some US insurers stopped covering compounded semaglutide after the FDA shortage delisting. Orlistat sits outside all of that — it's been off-shortage forever and the personal-import lane is unaffected.

2. You tried GLP-1 and didn't tolerate it. GLP-1 GI side effects (nausea, vomiting, constipation) hit somewhere between 30-50% of new users in titration. Some people genuinely cannot keep food down on semaglutide. Switching to orlistat trades one GI problem for a different GI problem — but they're different mechanisms and a meaningful subset of GLP-1 quitters tolerate orlistat fine. (See GLP-1 GI side effects management for the GLP-1 troubleshooting tree before you give up on it.)

3. BMI 27-30 with a low-fat diet you'll actually maintain. Orlistat's efficacy curve is fat-intake dependent. If your dietary fat is already 20% of calories, orlistat doesn't have much to block. If it's 35-40% (typical Western diet), orlistat captures meaningful triglyceride. The drug pairs with a moderately-low-fat diet better than GLP-1 pairs with anything specific.

4. Cost floor is hard. GLP-1 generic at $80-150/mo is already the cheapest legitimate route to that molecule. Orlistat generic at $15-50/mo is half to a fifth of that. If you're on the personal-import lane purely for cost reasons and the modest weight-loss target is acceptable, orlistat is the lowest-cost legitimate weight-management drug there is.

For a broader framework on which weight-management drug fits which person, our GLP-1 comprehensive guide walks the full ladder — orlistat sits at the bottom rung as the operational-friction-low-but-efficacy-modest option.

When orlistat is the wrong pick

If your goal is greater than ~10% body weight loss, orlistat isn't the drug. The ceiling at one year is in the 6-7% range even with strict adherence. Sustainable lifestyle change adds more than the drug does after year one.

If you eat unpredictably — restaurant meals you don't plan, social eating with surprise high-fat dishes — the bathroom risk turns into bathroom roulette. The drug doesn't know which meal was high-fat; your colon finds out 4-6 hours later.

If you're using it as an "eat what I want" license, the drug actively punishes that. People who use orlistat as a behavioral conditioner (high-fat meal → consequence) report the cleanest outcomes; people who use it as a license report the worst.

What to do this month if you're considering it

1. If you haven't tried GLP-1 yet, try GLP-1 first. The efficacy gap is too large to skip. Generic semaglutide injection or oral runs $80-150/mo through this lane and the GI side effects are usually titration-manageable.
2. If GLP-1 is contraindicated or you've tried and quit, order vitamin D 25(OH) and a baseline lipid panel. Quest or LabCorp, $30-80, no prescription.
3. Start at 60mg three times daily for the first 2-4 weeks if you can — even if you intend to land on 120mg. The lower starting dose lets you map your personal GI tolerance against meals before the full-strength hit.
4. Pair with a daily fat-soluble multivitamin, taken at bedtime. Non-negotiable past week 4.
5. Track meals and bathroom timing for the first month. The drug's footprint is statistical — you can predict ~30% of fat will exit, but not which 30% from which meal. People who learn their pattern early stay on the drug longer.

If you tolerate the first month, you'll likely tolerate the next twelve. Most quitters quit early.

A note on bias.

We route orlistat orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Slimtop (by Healing Pharma) and Reeshape (by Meyer Organics) ship in BOTH 60mg (Alli-equivalent) and 120mg (Xenical-equivalent) doses; Obelit (by Intas Pharmaceuticals), Orlica (by Torrent Pharmaceuticals), Orliford (by Banford), and Orligal (by Signature Pharmaceuticals) ship 120mg only. We don't route brand Xenical or Alli. Stock rotates between which generic ships in any given week — the molecule is identical across all six.

For reference on operations: crypto-only checkout (BTC, USDT, LTC, XMR, ETH via NOWPayments), 2 weeks standard lead time with 2-4 week customs variance, reship once free if tracking shows lost in transit, second reship also free, crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]) — no live chat, no phone. Crypto-only is the deliberate choice that lets the markup tier sit at $15-50/month instead of where card-network fees would push it.

So we have a financial reason to want this article to lead you toward "give it a try."

Read this with that in mind. The protocol above is what I'd tell a friend, not what maximizes reorder rate. For most people reading this in 2026, the friend-advice answer is: try GLP-1 first. Orlistat is the right drug for a specific list of situations, and that list is shorter than the GLP-1 candidate list.

Sources:

• Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-161. PMID 14693982
• FDA Xenical (orlistat 120mg) prescribing information, NDA 20-766 (1999, current revision); FDA Alli (orlistat 60mg) OTC monograph, NDA 21-887 (2007).
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021;384:989. PMID 33567185
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024
• Cheplapharm acquisition of Xenical from Roche, 2018, public corporate filings.
• LiberaCure internal catalog audit, weight-management vertical, 2026-04-17 (six-brand orlistat lineup verified active).

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.